$MRNA QuantLogix Newsdesk · 08/26/2026, 2:15 PM UTC

MRNA Therapeutics Sector Outlook 2026-2035 Profiles Multiple Platform Players

What happened

A newly published market outlook report covering the mRNA therapeutics landscape from 2026 through 2035 profiles several companies active in the space, including Moderna (MRNA), BioNTech, CureVac, Arcturus Therapeutics, Providence Therapeutics, RNAimmune, and Recode Therapeutics. The report examines pipeline developments, platform diversification beyond infectious disease, and competitive positioning across the sector. Moderna remains among the largest publicly traded names in the cohort by market capitalization.

The QL Read

MRNA carries a composite signal of 69/100 while the stock is down 4.65% on the session to $151.20. Market breadth stands at 51.3% advancing, placing sector-level developments from the report against a backdrop of individual-name session weakness.

Source: GlobeNewswire Inc. — "mRNA Therapeutics Market Outlook Report 2026-2035 Featuring Profiles of Arcturus Therapeutics, BioNTech, CureVac, Moderna, Providence Therap" — 2026-08-26T13:46:00Z

Not financial advice. QuantLogix is a research platform; nothing in this brief constitutes a recommendation to buy or sell any security. We summarize public news with attribution to the original publisher; visit the source above for the full original article.